/PRNewswire/ The "Global IV & Oral Iron Drugs Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com s offering. The global IV.
09.02.2024 - HBC had gross operating revenues of NOK 47.4m (33.6m) in the fourth quarter and NOK 218.5m (120.4m) for the full year. Adjusted for the sale of assets in the second quarter, operating revenues were NOK 194.9m for the full year, representing an .
Test your knowledge of iron deficiency anemia in this clinician quiz, focused on gastrointestinal evaluation of IDA based on recommendations from the American Gastrointestinal Association's 2020 guidelines.
According to a new systematic review and meta-analysis, roxadustat's efficacy remains consistent across varying inflammation levels in patients with chronic kidney disease.